1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CANbridge Pharmaceuticals Inc.
  6. News
  7. Summary
    1228   KYG1821D1097

CANBRIDGE PHARMACEUTICALS INC.

(1228)
  Report
Delayed Hong Kong Stock Exchange  -  05/20 04:08:13 am EDT
4.220 HKD   +1.20%
05/17CANbridge Pharma Presents Initial Data from Gene Therapy Research at US Medical Conference
MT
05/12CANbridge Pharmaceuticals Inc. Appoints Pauline Li as Senior Vice President of Clinical Development and Operations
CI
04/03CANbridge Pharmaceuticals Inc. Announces Executive Changes
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

CANbridge Pharmaceuticals CAN108 New Drug Application (NDA), for Alagille Syndrome, Accepted by China's National Medical Products Administration

01/19/2022 | 09:59am EDT

Beijing, China, Cambridge, Massachusetts - CANbridge Pharmaceuticals Inc., ('CANbridge,' stock code 1228.HK) a leading China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced that the Chinese National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for CAN108 (maralixibat oral solution (LIVMARLI TM)) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older. CANbridge anticipates that the application will be granted priority review, upon the close of the publicity period of the priority review process, on January 17th.

LIVMARLI TM (maralixibat) oral solution was recently approved by the US Food and Drug Administration (FDA) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older.

CANbridge and Mirum Pharmaceuticals signed an exclusive license agreement for the development and commercialization of maralixibat (CAN108) in Greater China last year. Under the terms of the agreement, CANbridge has the right to develop and commercialize CAN108 for three indications: Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia (BA) in Greater China.

'That the NMPA has accepted the NDA, which we anticipate will also receive priority review, for CAN108 for Alagille syndrome, our first candidate in rare liver disease, only 3 months after Maralixibat received FDA market approval, showcases our regulatory expertise and highlights the expanding list of indications we target,' said James Xue, Ph.D., CANbridge Founder, Chairman and CEO. 'We look forward to developing this treatment in China, where it could bring much-needed relief to patients and their families.'

About Alagille syndrome (ALGS

Alagille syndrome (ALGS) is a rare autosomal dominant disorder that affects multiple organs, including the liver, heart, bones, and eyes. Cholestatic liver disease is the most common form of it, and pruritus (severe itching) is the most severe clinical manifestation, in addition to jaundice, xanthomas, and hepatomegaly, which usually occur in infancy[1]. Pruritus may lead to skin mutilation, emotional disorder, interruption of sleep and school learning activities[2], seriously affecting children's growth, development, and quality of life[3]. Severe cholestatic pruritus is also an indication for liver transplantation[4]. According to Frost & Sullivan, there were 68,000 ALGS patients in the world, and 7400 patients in China in 2020.

About Maralixibat

LIVMARLI (Maralixibat) is a barely absorbed ileal bile acid transporter (IBAT) inhibitor that blocks the enterohepatic circulation of bile acids, reduces bile acid levels in the liver and serum, reduces the resultant liver injury and relieves pruritus. LIVMARLI TM is the first and, currently, only FDA-approved medication to treat cholestatic pruritus associated with Alagille syndrome.

Maralixibat is an oral drug that, in addition to ALGS, is under advanced clinical development for the treatment of other cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC) and biliary atresia (BA), and has been granted Breakthrough Therapy and Innovative Drugs for Rare Diseases designations by the FDA. Mirum Pharmaceuticals Inc. is conducting a Phase 3 clinical trial of Maralixibat in PFIC in North America, Europe, Asia, and South America. A global Maralixibat phase 2b clinical trial (EMBARK) in BA is also underway, for which CANbridge is managing the China sites.

About CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. ('CANbridge,' stock code: 1228.HK) is a China-based global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies.

CANbridge has a comprehensive and differentiated pipeline of 13 drug assets with significant market potential, targeting some of the most prevalent rare diseases and rare oncology.

These include Hunter syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia (BA) as well as glioblastoma multiforme (GBM).

CANbridge strategically combines global collaborations and internal research to build and diversify its drug portfolio and invest in next-generation gene therapy technologies for rare disease treatments. CANbridge global partners include, but are not limited to, Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, the University of Massachusetts Medical School (UMass), the University of Washington School of Medicine, LogicBio and Scriptr.

Contact:

CANbridge Pharmaceuticals Inc.

E: ir@canbridgepharma.com

Media

Deanne Eagle

Planet Communications

E: deanne@planetcommunications.nyc

T: 917.837.5866

[1] Binita M. Kamath et al. JPGN. 2018;67: 148-156

[2] Elisofon et al. JPGN. 2010;51: 759-765

[3] Abetz-Webb et al. Hepatology. 2014, 60(4), 526-527

[4]Guidelines for the Management of Cholestatic Liver Diseases (2021)

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CANBRIDGE PHARMACEUTICALS INC. 1.20% 4.22 Delayed Quote.-52.48%
MIRUM PHARMACEUTICALS, INC. 5.66% 25.58 Delayed Quote.60.38%
All news about CANBRIDGE PHARMACEUTICALS INC.
05/17CANbridge Pharma Presents Initial Data from Gene Therapy Research at US Medical Confere..
MT
05/12CANbridge Pharmaceuticals Inc. Appoints Pauline Li as Senior Vice President of Clinical..
CI
04/03CANbridge Pharmaceuticals Inc. Announces Executive Changes
CI
03/28CANbridge Pharmaceuticals Inc. Announces First Patient Has Been Dosed in the Can106 Pha..
CI
03/24CANbridge Announces Financial Results and Corporate Updates for the Twelve Months Ended..
AQ
03/23CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended Decembe..
CI
02/25Canbridge Pharmaceuticals Inc. Announces Approval of Can108 for Rare Liver Disease, Ala..
CI
02/16CANbridge Pharmaceuticals Inc. Announces Board Changes
CI
02/07CANbridge Pharmaceuticals Inc. Reports Positive Top-Line Can106 Phase 1 Data
CI
01/19CANbridge Pharmaceuticals CAN108 New Drug Application (NDA), for Alagille Syndrome, Acc..
AQ
More news
Financials
Sales 2022 90,2 M 13,5 M 13,5 M
Net income 2022 -707 M -106 M -106 M
Net cash 2022 926 M 138 M 138 M
P/E ratio 2022 -2,17x
Yield 2022 -
Capitalization 1 526 M 228 M 228 M
EV / Sales 2022 6,66x
EV / Sales 2023 3,99x
Nbr of Employees 183
Free-Float 59,7%
Chart CANBRIDGE PHARMACEUTICALS INC.
Duration : Period :
CANbridge Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CANBRIDGE PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 4,22 HKD
Average target price 12,37 HKD
Spread / Average Target 193%
EPS Revisions
Managers and Directors
James Xue Chairman & Chief Executive Officer
Glenn Hassan Chief Financial Officer
Gerald Cox Chief Medical & Development Strategist Officer
Minnie Ke VP-Clinical Development & Medical Affairs
Pauline Li Senior VP-Operations & Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
CANBRIDGE PHARMACEUTICALS INC.-52.48%228
MERCK KGAA-24.05%79 076
KYOWA KIRIN CO. LTD.-13.65%11 377
SK BIOPHARMACEUTICALS CO., LTD.-11.21%5 308
YUHAN CORPORATION-5.80%3 126
BETTA PHARMACEUTICALS CO., LTD.-43.32%2 808